Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-V7 and CTC correlation study in first-line abiraterone-treated mCRPC
2016-002735-16Phase 3Terminated
- Sponsor
- Otto von Guericke University Magdeburg
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Otto von Guericke University Magdeburg. Primary endpoint: Radiologic progression-free survival. Started Oct 2016; status: terminated.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-002735-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002735-16.